Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA

mAbs

Volumn 8, Issue 8, 2016, Pages 1425-1434

  Larrick, James W ^a   Alfenito, Mark R ^b   Scott, Jamie K ^c   Parren, Paul W H I ^d,e   Burton, Dennis R ^f   Bradbury, Andrew R M ^g   Lemere, Cynthia A ^h   Messer, Anne ⁱ   Huston, James S ^j   Carter, Paul J ^k   Veldman, Trudi ^l   Chester, Kerry A ^m   Schuurman, Janine ^d   Adams, Gregory P ⁿ   Reichert, Janice M ^o  

^a Panorama Research Institute   (United States)

^b EnGen Bio Inc   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

^d GENMAB   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ Regenerative Research Foundation   (United States)

^j The Antibody Society and Huston Bio Consulting LLC   (United States)

^k GENENTECH INC   (United States)

^l ABBVIE INC   (United States)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ Viventia Bio Inc   (United States)

^o Antibody Society   (United States)

more..

Author keywords

Antibody engineering; antibody repertoire; antibody drug conjugates; bispecific antibodies; international non proprietary names; next generation sequencing; reproducibility

Indexed keywords

5' NUCLEOTIDASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CANCER VACCINE; CD19 ANTIGEN; CD20 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; DARATUMUMAB; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TRASTUZUMAB EMTANSINE; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN; ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY ENGINEERING; CELL THERAPY; CLINICAL TRIAL (TOPIC); COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; HUNTINGTON CHOREA; INFLAMMATORY BOWEL DISEASE; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN PROCESSING; T LYMPHOCYTE; ANIMAL; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES; HUMANS; PROTEIN ENGINEERING;

EID: 84991038772     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1227665     Document Type: Article

References (22)

1. D.C.Butler, A.Messer. Bifunctional anti-huntington proteasome-directed intrabodies mediate efficient degradation of mutant huntington exon 1 protein fragments. PLoS One 2011; 6:e29199.
2. S.N.Joshi, D.C.Butler, A.Messer. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs 2012; 4:686–693.
3. J.-M.Lecerf, T.L.Shirley, Q.Zhu, A.Kazantsev, P.Amersdorfer, D.E.Housman, A.Messer, J.S.Huston. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001; 98:4764–69.
4. W.J.Wolfgang, T.W.Miller, J.M.Webster, J.S.Huston, L.M.Thompson, J.L.Marsh, A.Messer. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005; 102:11563–68.
5. A.Snyder-Keller, J.A.McLear, T.Hathorn, A.Messer. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol 2010; 41:1078–85. doi:10.1097/NEN.0b013e3181f530ec.
6. B.Yuan, M.R.Sierks. Intracellular targeting and clearance of oligomeric alpha synuclein alleviates toxicity in mammalian cells. Neurosci Lett 2009; 459:16–8.
7. B.Spencer, S.Emadi, P.Desplats, S.Eleuteri, S.Michael, K.Kosberg, J.Shen, E.Rockenstein, C.Patrick, A.Adame, T.Gonzalez, M.Sierks, E.Masliah. ESCRT-mediated uptake and degradation of brain- targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 2014; 22:1753–67.
8. W.D.Marcus, H.Wang, D.Lohr, M.R.Sierks, S.M.Lindsay. Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. Biochem Biophys Res Commun 2006; 342:1123–9.
9. B.Yuan, M.R.Sierks. Intracellular targeting and clearance of oligomeric alpha synuclein alleviates toxicity in mammalian cells. Neurosci Lett 2009; 459:16–8.
10. W.Xin, S.Emadi, S.Williams, Q.Liu, P.Schulz, P.He, N.B.Alam, J.Wu, M.R.Sierks. Toxic oligomeric alpha-synuclein variants present in human Parkinson's disease brains are differentially generated in mammalian cell models. Biomolecules 2015; 5:1634–51.
11. S.M.Williams, P.Schulz, M.R.Sierks. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci 2016; 43:3–16.
12. E.Valera, E.Masliah. Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 2016; 10.1111/jnc.13529
13. E.Valera, B.Spencer, E.Masliah. Immunotherapeutic approaches in Parkinson's disease and related disorders. Neurotherapeutics 2016; 13:179–89.
14. M.B.Fares, B.Maco, A.Oueslati, E.Rockenstein, N.Ninkina, V.L.Buchman, E.Masliah, H.A.Lashuel. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease. Proc Natl Acad Sci U S A 2016; 113:E912–21.
15. D.L.Price, E.Rockenstein, M.Mante, A.Adame, C.Overk, B.Spencer, K.X.Duong-Polk, D.Bonhaus, J.Lindsey, E.Masliah. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy bodies. Sci Rep 2016; 6:#29523, 1–10.
16. L.Breydo, D.Kurouski, S.Rasool, S.Milton, J.W.Wu, V.N.Uversky, I.K.Lednev, C.G.Glabe. Structural differences between amyloid beta oligomers. Biochem Biophys Res Commun 2016; 477:700–5.
17. E.M.Knight, S.H.Kim, J.C.Kottwitz, A.Hatami, R.Albay, A.Suzuki, A.Lublin, C.M.Alberini, W.L.Klein, P.Szabo, N.R.Relkin, M.Ehrlich, C.G.Glabe, S.Gandy, J.W.Steele. Effective anti-Alzheimer's Aβ oligomer subtype. Neurol Neuroimmunol Neuroinflamm 2016; 3:e237.
18. H.Cynis, J.L.Frost, H.Crehan, C.A.Lemere. Immunotherapy targeting pyroglutamate-3 Aβ:prospects and challenges. Mol Neurodegen 2016; 11:48, 1–11.
19. Q.Shi, K.J.Colodner, S.B.Matousek, K.Merry, S.Hong, J.E.Kenison, J.L.Frost, K.X.Le, S.Li, J.C.Dodart, B.J.Caldarone, B.Stevens, C.A.Lemere. Complement C3-dependent mice fail to display age-related hippocampal decline. J Neurosci 2015; 35:13029–42.
20. S.Hong, V.F.Beja-Glasser, B.M.Nfonoyim, A.Frouin, S.Li, S.Ramakrishnan, K.M.Merry, Q.Shi, A.Rosenthal, B.A.Barres, C.A.Lemere, D.J.Selkoe, B.Stevens. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352:712–6.
21. J.M.Reichert. Antibodies to watch in 2016. MAbs 2016; 8:197–204.
22. T.D.Jones, P.J.Carter, A.Plückthun, M.Vásquez, R.G.Holgate, I.Hötzel, A.G.Popplewell, P.W.Parren, M.Enzelberger, H.J.Rademaker, et al. The INNs and outs of antibody nonproprietary names. MAbs 2016; 8:1–9.